Roche vs SelectQuote

Wirz Launches Healthcare Consulting Unit Wirz Pulse

Swiss agency group Wirz has launched 'Wirz Pulse', a specialized consulting offering for the healthcare market, targeting hospitals, insurers, and pharma/medtech companies. The service aims to support healthcare organizations in positioning, change management, and growth. Wirz will collaborate with organizations to develop a strategic direction translated into positioning, culture, offerings, communication, and experiences. Six programs cover transformation, brand identity, patient journey, work culture, innovation, and digital experience. The launch responds to labor shortages, cost pressure, digitalization, and evolving patient needs, as well as new fields like personalized medicine and longevity. Existing healthcare mandates include Roche, University Hospital Zurich, CSS, Interpharma, and Rheumaliga Schweiz, from which Wirz derived recurring challenges and success factors.

• Wirz Group launches 'Wirz Pulse' consulting service for healthcare sector.
• Targets hospitals, insurers, pharma, and medtech companies.
• Offers six programs: transformation, brand identity, patient journey, work culture, innovation, digital experience.

Roche and Ypsomed Stay Top in Swiss Reputation Ranking

Swissreputation Group and Pressrelations Schweiz analyzed nearly 90,000 reputation-relevant statements from about 4,000 Swiss online and print sources using an AI-supported method to evaluate media reputation for 40 pharma and medtech companies. The study measured presence (coverage and reach) and tonality (positive/negative reporting) and calculated a Reputation Score (0–100) for each company across six reputation dimensions. In Pharma & Biopharma, Roche ranks first (ahead of MSD, Novartis, Sandoz and AstraZeneca). In MedTech & Diagnostics, Ypsomed remains first (ahead of Medacta, Straumann Group, Alcon and Sonova). The study notes products/services, innovation and economic performance tended to improve media reputation, while workplace issues (layoffs, relocations) and ESG/legal problems harmed reputation. The article was published on 2026-08-13.

• Swissreputation Group and Pressrelations Schweiz analyzed nearly 90,000 reputation-relevant statements from about 4,000 Swiss online and print sources using an AI-supported method.
• The study measured presence and tonality for 40 pharma and medtech companies and computed a Reputation Score between 0 and 100 across six reputation dimensions.
• In the Pharma & Biopharma category, Roche ranked first, followed by MSD, Novartis, Sandoz and AstraZeneca.

Roche Pharma Day 2026 announced

Roche Pharma Day 2026 will be held on Monday, 28th September 2026, 09:00am BST. More details available via the investor update.

10-K Financial Filing Analysis for SelectQuote (2026-08-25)

SelectQuote, Inc. reported its annual financial results and business overview in its Form 10-K for the fiscal year ended June 30, 2026. The company operates a technology-driven, direct-to-consumer distribution platform for insurance policies and healthcare services, leveraging proprietary AI/ML algorithms to optimize lead acquisition and customer lifetime value (LTV). During fiscal 2026, SelectQuote accelerated strategic investments in operational AI—including contact center conversational voice systems—while intentionally expanding its Healthcare Services division (anchored by SelectRx pharmacy operations and SelectPatient Management) and de-emphasizing its Auto & Home distribution business. Top carrier partners UnitedHealthcare, Humana, and Aetna represented a combined 64% of consolidated revenues. The company also disclosed active corporate initiatives including an NYSE minimum share price deficiency notice received in March 2026, for which it is seeking shareholder approval to implement a reverse stock split, and ongoing legal defense regarding a federal False Claims Act qui tam matter.

• SelectQuote's top three carrier partners (UnitedHealthcare at 39%, Humana at 13%, and Aetna at 12%) generated 64% of total consolidated revenue in fiscal year 2026.
• For the fiscal year ended June 30, 2026, the company sold over 635,000 Senior segment policies (89% Medicare Advantage) and generated more than $200 million in new premiums across its Life and Auto & Home segments.
• SelectRx grew its active patient base to over 109,000 members as of June 30, 2026, backed by fulfillment expansion at its Olathe, Kansas facility.